Takeda Pharmaceutical Co Ltd (TKD.MU)

Munich - Munich Prezzo differito. Valuta in EUR.

Aggiungi a watchlist

24,28

-0,04

(-0,16%)

In data: 08:05AM CEST. Mercato aperto.

Capitalizzazione	N/D
Beta (mensile su 5 anni)	N/D
Rapporto PE (ttm)	N/D
EPS (ttm)	N/D
Prossima data utili	31 lug 2024
Rendimento e dividendo (futuro)	N/D (N/D)
Data ex dividendo	N/D
Stima target 1A	N/D

Tutte

GlobeNewswire
HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
— Third major market authorization application based on data from the FRESCO-2 global Phase III trial —HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (“HUTCHMED”) today announced that Takeda (TSE:4502/NYSE:TAK) has submitted a New Drug Application (“NDA”) to the Ministry of Health, Labour and Welfare (“MHLW”) in Japan for the approval of fruquintinib for the treatment of adult patients with previously
GlobeNewswire
HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet
— Publication shows FRESCO-2 demonstrated treatment with fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer (0.66 HR) — — Data support regulatory submissions in the U.S., Europe and Japan during 2023 — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J. and OSAKA, Japan and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) and Takeda (TSE:4502, NYSE:TAK) today announced that results